Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Eddy Shih-Hsin Yang

Eddy Shih-Hsin Yang

Vice Chairman(Translational Science)
University of Alabama at Birmingham
USA

Biography

Eddy Shih-Hsin Yang, MD, PhD is an Associate Professor in the Department of Radiation Oncology at the University of Alabama at Birmingham (UAB), Endowed Chair of ROAR Southeast Cancer Foundation, Medical Director of the UAB Molecular Tumor Board, and member of the Clinical Trials Review Committee for the UAB Comprehensive Cancer Center. As a physician-scientist oncologist, he has particular interest in targeting of DNA repair pathways to enhance the therapeutic ratio and understanding the contributions of DNA damage and genome instability to carcinogenesis. He also strives to uncover potential biomarkers to inform and guide therapy in a more personalized medicine approach. He directs the UAB Nanostring Laboratory, which houses the nCounter platform by Nanostring Technologies. This technology allows for targeted analysis of molecular pathways at multiple levels, including DNA copy number variation, gene expression, microRNA, and protein analysis. His research in these pathways has led him to focus on breast, genitourinary, and head and neck cancers. His work has been supported by various funding sources, including the NIH Breast SPORE at UAB, the Susan G. Komen Foundation, the Department of Defense, the American Association for Cancer Research, and the Sidney Kimmel Foundation. He also has an excellent track record of productivity in DNA repair and cancer research. Ultimately, as a translational researcher, he hopes to implement findings from the laboratory into the clinic, whether from a therapeutic or prevention perspective.

Research Interest

particular interest in targeting of DNA repair pathways to enhance the therapeutic ratio and understanding the contributions of DNA damage and genome instability to carcinogenesis